MET and non-small cell lung carcinoma: In an expansion cohort phase I study (PROFILE 1001, NCT00585195), crizotinib, a multi-kinase inhibitor, showed encouraging ORRs of 44% (8/18) in patients with MET exon 14-altered NSCLC and 50% (3/6) in patients with MET amplification (MET/CEP7 ratio ≥5) NSCLC.